Genetic Biomarker Discovery for Metastatic Prostate Cancer

Inclusion Criteria: * Men age 18 years old and older. * Histologically proven diagnosis of prostate cancer. * Radiographic evidence of non-regional lymph node involvement, pelvic lymph node recurrence, and/or bone metastases. * Requiring a clinically directed biopsy or resection of tumor at Mayo Clinic Rochester. * Receiving local therapy for metastatic disease with radiation, ablative therapies, and/or surgery at Mayo Clinic Rochester. * Willingness to provide blood sample prior to receipt of treatment, as well as after neoadjuvant androgen deprivation therapy and at 3 months and 6 months after radiation, ablation, or surgery. * Absence of a second active malignancy. * An understanding of the protocol and its requirements, risks, and discomforts. * The ability and willingness to sign an informed consent. Exclusion Criteria: * Inability on the part of the patient to understand the informed consent or be compliant with the protocol. * History of a serious or life-threatening allergic reaction to local anesthetics (i.e., lidocaine, xylocaine).